AnaptysBio (NASDAQ:ANAB) Sees Unusually-High Trading Volume

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) saw strong trading volume on Wednesday . 515,087 shares changed hands during mid-day trading, an increase of 97% from the previous session’s volume of 261,156 shares.The stock last traded at $19.50 and had previously closed at $19.63.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. StockNews.com assumed coverage on AnaptysBio in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Guggenheim increased their price objective on AnaptysBio from $44.00 to $45.00 in a research report on Friday, May 12th. Wedbush reduced their price objective on AnaptysBio from $29.00 to $26.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 8th. TD Cowen started coverage on AnaptysBio in a research report on Thursday, May 18th. They set an “outperform” rating on the stock. Finally, JPMorgan Chase & Co. upgraded AnaptysBio from an “underweight” rating to a “neutral” rating and reduced their price objective for the company from $31.00 to $30.00 in a research report on Monday, May 22nd. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $33.67.

AnaptysBio Stock Performance

The firm has a 50-day moving average of $19.30 and a 200-day moving average of $20.54. The firm has a market capitalization of $520.38 million, a P/E ratio of -3.81 and a beta of -0.16.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($1.50) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.15. AnaptysBio had a negative return on equity of 65.52% and a negative net margin of 1,113.38%. The business had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $5.50 million. Equities analysts anticipate that AnaptysBio, Inc. will post -6.52 EPS for the current fiscal year.

Institutional Investors Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System lifted its holdings in AnaptysBio by 4.5% in the 2nd quarter. California State Teachers Retirement System now owns 23,523 shares of the biotechnology company’s stock worth $478,000 after buying an additional 1,003 shares during the period. Alliancebernstein L.P. lifted its stake in shares of AnaptysBio by 13.7% in the 2nd quarter. Alliancebernstein L.P. now owns 32,520 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 3,920 shares during the period. Wells Fargo & Company MN lifted its stake in shares of AnaptysBio by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 23,430 shares of the biotechnology company’s stock valued at $477,000 after purchasing an additional 6,950 shares during the period. Public Employees Retirement System of Ohio lifted its stake in shares of AnaptysBio by 28.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 23,137 shares of the biotechnology company’s stock valued at $471,000 after purchasing an additional 5,165 shares during the period. Finally, Woodline Partners LP lifted its stake in shares of AnaptysBio by 125.1% in the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock valued at $21,043,000 after purchasing an additional 574,987 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.